Shared parameter models for the joint analysis of longitudinal data and event times - PubMed (original) (raw)
Comparative Study
. 2006 Jan 15;25(1):143-63.
doi: 10.1002/sim.2249.
Affiliations
- PMID: 16025541
- DOI: 10.1002/sim.2249
Comparative Study
Shared parameter models for the joint analysis of longitudinal data and event times
Edward F Vonesh et al. Stat Med. 2006.
Abstract
Longitudinal studies often gather joint information on time to some event (survival analysis, time to dropout) and serial outcome measures (repeated measures, growth curves). Depending on the purpose of the study, one may wish to estimate and compare serial trends over time while accounting for possibly non-ignorable dropout or one may wish to investigate any associations that may exist between the event time of interest and various longitudinal trends. In this paper, we consider a class of random-effects models known as shared parameter models that are particularly useful for jointly analysing such data; namely repeated measurements and event time data. Specific attention will be given to the longitudinal setting where the primary goal is to estimate and compare serial trends over time while adjusting for possible informative censoring due to patient dropout. Parametric and semi-parametric survival models for event times together with generalized linear or non-linear mixed-effects models for repeated measurements are proposed for jointly modelling serial outcome measures and event times. Methods of estimation are based on a generalized non-linear mixed-effects model that may be easily implemented using existing software. This approach allows for flexible modelling of both the distribution of event times and of the relationship of the longitudinal response variable to the event time of interest. The model and methods are illustrated using data from a multi-centre study of the effects of diet and blood pressure control on progression of renal disease, the modification of diet in renal disease study.
Copyright 2005 John Wiley & Sons, Ltd.
Similar articles
- Conditional mixed models adjusting for non-ignorable drop-out with administrative censoring in longitudinal studies.
Li J, Schluchter MD. Li J, et al. Stat Med. 2004 Nov 30;23(22):3489-503. doi: 10.1002/sim.1926. Stat Med. 2004. PMID: 15505888 - Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease.
Schluchter MD, Greene T, Beck GJ. Schluchter MD, et al. Stat Med. 2001 Apr 15;20(7):989-1007. doi: 10.1002/sim.720. Stat Med. 2001. PMID: 11276031 Clinical Trial. - Partly conditional survival models for longitudinal data.
Zheng Y, Heagerty PJ. Zheng Y, et al. Biometrics. 2005 Jun;61(2):379-91. doi: 10.1111/j.1541-0420.2005.00323.x. Biometrics. 2005. PMID: 16011684 - Statistical methods for analysing longitudinal data in delirium studies.
Adamis D. Adamis D. Int Rev Psychiatry. 2009 Feb;21(1):74-85. doi: 10.1080/09540260802675346. Int Rev Psychiatry. 2009. PMID: 19219714 Review. - Modelling placebo response in depression trials using a longitudinal model with informative dropout.
Gomeni R, Lavergne A, Merlo-Pich E. Gomeni R, et al. Eur J Pharm Sci. 2009 Jan 31;36(1):4-10. doi: 10.1016/j.ejps.2008.10.025. Epub 2008 Nov 8. Eur J Pharm Sci. 2009. PMID: 19041717 Review.
Cited by
- Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Nangaku M, Herrington WG, Goto S, Maruyama S, Kashihara N, Ueki K, Wada J, Watada H, Nakashima E, Lee R, Massey D, Mayne KJ, Tomita A, Haynes R, Hauske SJ, Kadowaki T. Nangaku M, et al. Clin Exp Nephrol. 2024 Jun;28(6):588-595. doi: 10.1007/s10157-024-02489-4. Epub 2024 Apr 20. Clin Exp Nephrol. 2024. PMID: 38643286 Free PMC article. Clinical Trial. - An Introduction and Practical Guide to Strategies for Analyzing Longitudinal Data in Clinical Trials of Smoking Cessation Treatment: Beyond Dichotomous Point-Prevalence Outcomes.
Kypriotakis G, Bernstein SL, Bold KW, Dziura JD, Hedeker D, Mermelstein RJ, Weinberger AH. Kypriotakis G, et al. Nicotine Tob Res. 2024 Jun 21;26(7):796-805. doi: 10.1093/ntr/ntae005. Nicotine Tob Res. 2024. PMID: 38214037 Review. - Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial. - A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontán F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL; CKD-EPI Clinical Trials Consortium. Inker LA, et al. Nat Med. 2023 Jul;29(7):1867-1876. doi: 10.1038/s41591-023-02418-0. Epub 2023 Jun 17. Nat Med. 2023. PMID: 37330614